Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxin Danshen Dripping Pills in Coronary Artery Disease With Depression or Anxiety
ChiCTR2100051523Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Compound Danshen in coronary arteriosclerosis, major depressive disorder (MDD), anxiety disorder and 1 more, sponsored by Tongji Hospital. Primary endpoints: Change in Patient Health Questionnaire-9 (PHQ-9) depression score, Change in Generalized Anxiety Disorder-7 (GAD-7) anxiety score and 1 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
Compound Danshen
03
Conditions
coronary arteriosclerosismajor depressive disorder (MDD)anxiety disorderangina pectoris
Beyond the preview
Go deeper on ChiCTR2100051523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051523.